Compare WFG & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFG | GRFS |
|---|---|---|
| Founded | 1955 | 1940 |
| Country | Canada | Spain |
| Employees | N/A | 25247 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.9B |
| IPO Year | 2007 | N/A |
| Metric | WFG | GRFS |
|---|---|---|
| Price | $71.69 | $7.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $89.50 | $10.15 |
| AVG Volume (30 Days) | 155.8K | ★ 701.4K |
| Earning Date | 04-29-2026 | 07-28-2022 |
| Dividend Yield | ★ 2.03% | 1.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.05 | $4.49 |
| Revenue Next Year | $10.26 | $6.42 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.34 | $6.96 |
| 52 Week High | $76.99 | $11.14 |
| Indicator | WFG | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 61.36 | 44.51 |
| Support Level | $58.54 | $6.96 |
| Resistance Level | $76.77 | $7.73 |
| Average True Range (ATR) | 1.95 | 0.16 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 90.19 | 47.17 |
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.